GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Institutional Ownership

Moleculin Biotech (FRA:MOL) Institutional Ownership : 5.86% (As of Sep. 22, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Moleculin Biotech's institutional ownership is 5.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Moleculin Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Moleculin Biotech's Float Percentage Of Total Shares Outstanding is 97.32%.


Moleculin Biotech Institutional Ownership Historical Data

The historical data trend for Moleculin Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moleculin Biotech Institutional Ownership Chart

Moleculin Biotech Historical Data

The historical data trend for Moleculin Biotech can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 7.56 7.56 5.53 5.49 5.47 4.88 4.88 4.99 5.07 5.86

Moleculin Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Moleculin Biotech Business Description

Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Moleculin Biotech Headlines

No Headlines